Mineralys Therapeutics Valuation: A Closer Look at the Price-to-Book Ratio and DCF Model

Findell Capital's $9.5 million investment in Mineralys Therapeutics (MLYS) has sparked investor interest, given the company's recent funding round and growing momentum. MLYS' 252% year-to-date share price return has investors questioning if the stock is undervalued. The price-to-book ratio of 5.9x is above the US Biotechs industry average, suggesting investors are pricing in significant future potential. However, our DCF model suggests shares are trading nearly 49% below fair value.